Video
Dr. Mirza Discusses Niraparib Dose Modifications for Patients With Low Body Weight
Author(s):
Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, discusses a study of safety and dose modification for patients with low body weight receiving niraparib (Zejula) in the ENGOT-OV16/NOVA phase III trial during the 2018 Society of Gynecologic Oncology Annual Meeting.
Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, discusses a study of safety and dose modification for patients with low body weight receiving niraparib (Zejula) in the ENGOT-OV16/NOVA phase III trial during the 2018 Society of Gynecologic Oncology Annual Meeting.
Results of this retrospective analysis showed patients who had <77 kg body weight and/or <150,000/µL platelet counts had a greater risk of grade 3 or 4 thrombocytopenia, compared to patients who were heavier and had higher platelets counts, Mirza says.
Interestingly, the patients with lower body weight and platelet counts were able to remain on the 300-mg starting dose of niraparib. Only 3% of patients on the study discontinued treatment due to thrombocytopenia.
These data suggest that niraparib is very manageable, dose adjustments can allow patients to remain on the drug for a long time, and lower doses likely have the same efficacy as the 300-mg dose, Mirza explains.
